How much and how long: Tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Elie Traer, Michael W. Deininger

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

As the first clinically successful tyrosine kinase inhibitor (TKI), imatinib pioneered a new approach to treating patients with cancer. Dramatic results from chronic myeloid leukemia (CML) clinical trials spurred the development of TKIs for other malignancies such as acute myeloid leukemia as well as kidney and lung cancer. In CML, imatinib resistance led to the rapid development of dasatinib and nilotinib, more potent second-generation ABL kinase inhibitors that can often overcome imatinib resistance. While the clinical efficacy of TKIs in CML is well established, a number of important questions remain about the optimal dose and duration of therapy. Even the best initial dose for imatinib is still under investigation. Although laboratory and clinical studies had led to the prevailing view that continual inhibition of the BCR-ABL kinase was required for optimal efficacy, recent data on dasatinib have upended this notion and have led to a change in the recommended dosing schedule. The availability of dasatinib and nilotinib also begs the question of whether they might be superior to imatinib as first-line agents. Finally, the question of whether it may be possible to stop TKI therapy at least in some patients with CML has attracted considerable attention. More than 10 years after the introduction of imatinib, optimization of TKI therapy for CML continues.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
Volume10
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 2010

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Phosphotransferases
Therapeutics
Kidney Neoplasms
Acute Myeloid Leukemia
Imatinib Mesylate
Lung Neoplasms
Neoplasms
Appointments and Schedules
Clinical Trials
Dasatinib

Keywords

  • BCR-ABL
  • Dasatinib
  • Imatinib
  • Nilotinib

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology
  • Medicine(all)

Cite this

How much and how long : Tyrosine kinase inhibitor therapy in chronic myeloid leukemia. / Traer, Elie; Deininger, Michael W.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 10, No. SUPPL. 1, 06.2010.

Research output: Contribution to journalArticle

@article{505b0b2697ad47f8becb3182ac77e4e7,
title = "How much and how long: Tyrosine kinase inhibitor therapy in chronic myeloid leukemia",
abstract = "As the first clinically successful tyrosine kinase inhibitor (TKI), imatinib pioneered a new approach to treating patients with cancer. Dramatic results from chronic myeloid leukemia (CML) clinical trials spurred the development of TKIs for other malignancies such as acute myeloid leukemia as well as kidney and lung cancer. In CML, imatinib resistance led to the rapid development of dasatinib and nilotinib, more potent second-generation ABL kinase inhibitors that can often overcome imatinib resistance. While the clinical efficacy of TKIs in CML is well established, a number of important questions remain about the optimal dose and duration of therapy. Even the best initial dose for imatinib is still under investigation. Although laboratory and clinical studies had led to the prevailing view that continual inhibition of the BCR-ABL kinase was required for optimal efficacy, recent data on dasatinib have upended this notion and have led to a change in the recommended dosing schedule. The availability of dasatinib and nilotinib also begs the question of whether they might be superior to imatinib as first-line agents. Finally, the question of whether it may be possible to stop TKI therapy at least in some patients with CML has attracted considerable attention. More than 10 years after the introduction of imatinib, optimization of TKI therapy for CML continues.",
keywords = "BCR-ABL, Dasatinib, Imatinib, Nilotinib",
author = "Elie Traer and Deininger, {Michael W.}",
year = "2010",
month = "6",
doi = "10.3816/CLML.2010.s.003",
language = "English (US)",
volume = "10",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - How much and how long

T2 - Tyrosine kinase inhibitor therapy in chronic myeloid leukemia

AU - Traer, Elie

AU - Deininger, Michael W.

PY - 2010/6

Y1 - 2010/6

N2 - As the first clinically successful tyrosine kinase inhibitor (TKI), imatinib pioneered a new approach to treating patients with cancer. Dramatic results from chronic myeloid leukemia (CML) clinical trials spurred the development of TKIs for other malignancies such as acute myeloid leukemia as well as kidney and lung cancer. In CML, imatinib resistance led to the rapid development of dasatinib and nilotinib, more potent second-generation ABL kinase inhibitors that can often overcome imatinib resistance. While the clinical efficacy of TKIs in CML is well established, a number of important questions remain about the optimal dose and duration of therapy. Even the best initial dose for imatinib is still under investigation. Although laboratory and clinical studies had led to the prevailing view that continual inhibition of the BCR-ABL kinase was required for optimal efficacy, recent data on dasatinib have upended this notion and have led to a change in the recommended dosing schedule. The availability of dasatinib and nilotinib also begs the question of whether they might be superior to imatinib as first-line agents. Finally, the question of whether it may be possible to stop TKI therapy at least in some patients with CML has attracted considerable attention. More than 10 years after the introduction of imatinib, optimization of TKI therapy for CML continues.

AB - As the first clinically successful tyrosine kinase inhibitor (TKI), imatinib pioneered a new approach to treating patients with cancer. Dramatic results from chronic myeloid leukemia (CML) clinical trials spurred the development of TKIs for other malignancies such as acute myeloid leukemia as well as kidney and lung cancer. In CML, imatinib resistance led to the rapid development of dasatinib and nilotinib, more potent second-generation ABL kinase inhibitors that can often overcome imatinib resistance. While the clinical efficacy of TKIs in CML is well established, a number of important questions remain about the optimal dose and duration of therapy. Even the best initial dose for imatinib is still under investigation. Although laboratory and clinical studies had led to the prevailing view that continual inhibition of the BCR-ABL kinase was required for optimal efficacy, recent data on dasatinib have upended this notion and have led to a change in the recommended dosing schedule. The availability of dasatinib and nilotinib also begs the question of whether they might be superior to imatinib as first-line agents. Finally, the question of whether it may be possible to stop TKI therapy at least in some patients with CML has attracted considerable attention. More than 10 years after the introduction of imatinib, optimization of TKI therapy for CML continues.

KW - BCR-ABL

KW - Dasatinib

KW - Imatinib

KW - Nilotinib

UR - http://www.scopus.com/inward/record.url?scp=77957333261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957333261&partnerID=8YFLogxK

U2 - 10.3816/CLML.2010.s.003

DO - 10.3816/CLML.2010.s.003

M3 - Article

C2 - 20529804

AN - SCOPUS:77957333261

VL - 10

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - SUPPL. 1

ER -